智通财经APP讯,科伦博泰生物-B(06990)发布截至2024年12月31日止年度业绩,收入19.33亿元(人民币,下同),同比增长25.5%;净亏损2.67亿元,同比收窄53.5%;每股基本亏损1.20元。
集团2024年年度的收入同比增加,乃主要由于2024达成多个研发里程碑;及2024年开始药品销售。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.